Status:
COMPLETED
Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole
Lead Sponsor:
University Health Network, Toronto
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study involves the administration of a hypoxia marker, pimonidazole hydrochloride, taken orally approximately 24 hours before surgical resection of a pancreatic tumor in order to identify areas o...
Detailed Description
Intratumoral hypoxia (low oxygen concentration or pO2) occurs when oxygen consumption exceeds its delivery by the vascular system. Hypoxia is associated with adverse patient outcome in many human canc...
Eligibility Criteria
Inclusion
- age \> 18
- provisional diagnosis of pancreatic cancer
- scheduled resection at UHN
- consented to ICGC Pancreatic Cancer Genome Project
- surgery planned for \>2 days away (drug administration has to be 16-20hrs before surgery)
Exclusion
- not participating in ICGC
- contraindications to pimonidazole (allergy)
- surgery scheduled for same or next day (not enough time to arrange for drug administration)
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01248637
Start Date
October 1 2010
End Date
December 1 2017
Last Update
July 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9